
LMU physician Sebastian Kobold
Photo Credit: © LMU / Stephan Höck
Scientific Frontline: Extended "At a Glance" Summary
The Core Concept: An advanced form of immunotherapy in which Chimeric Antigen Receptor (CAR) T cells are genetically engineered to resist immunosuppressive signals found within solid tumors, enabling the immune system to effectively destroy cancer cells that were previously resistant to treatment.
Key Distinction/Mechanism: While standard CAR T-cell therapy is highly effective against blood cancers, it often fails against solid tumors because a metabolite called prostaglandin E2 (PGE2) suppresses the T cells' function. This new approach involves removing the specific receptors on the T cells that PGE2 binds to; by eliminating these binding sites, the T cells become "deaf" to the tumor's suppression signal and remain active to attack the malignancy.
Origin/History:
- 2024: Professor Sebastian Kobold’s research group at LMU University Hospital identifies that PGE2 blocks T cells in the tumor vicinity.
- 2026: The team, in cooperation with the University of Tübingen, publishes their success in engineering PGE2-resistant cells in Nature Biomedical Engineering.
Major Frameworks/Components:
- Chimeric Antigen Receptor (CAR) T Cells: Patient-derived immune cells modified to recognize specific cancer proteins (like CD19).
- Prostaglandin E2 (PGE2): An immunosuppressive metabolite in the tumor microenvironment that normally inhibits immune response.
- Receptor Knockout: The genetic removal of PGE2 receptors from T cells to prevent immunosuppression.

_MoreDetail-v3_x2_730x524.jpg)







.jpg)



